COVID-19 & CancerFree With $306M for serology research, NCI mobilizes labs, academic centers, grantees, contractors, and SBIR May 15, 2020Vol.46 No.20By Paul Goldberg
Conversation with The Cancer LetterCOVID-19 & CancerFree Nancy Davidson describes plans for reopening the Seattle Cancer Care Alliance as COVID-19 wave recedes May 15, 2020Vol.46 No.20By Paul Goldberg
Conversation with The Cancer LetterCOVID-19 & CancerFree Lessons from COVID-19:Leaders of six cancer centers in the DMV area tell us about caseloads, the outlook—and impact May 08, 2020Vol.46 No.19By Matthew Bin Han Ong
COVID-19 & CancerFree COVID-19 slams into the nation’s capital region; Here is the damage assessment at six institutions May 08, 2020Vol.46 No.19By Matthew Bin Han Ong
COVID-19 & CancerFree NCI receives $306 million in new money for COVID-19 serology test research;Details to follow at BSA meeting May 12 May 08, 2020Vol.46 No.19By Paul Goldberg
Drugs & TargetsFree FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC May 08, 2020Vol.46 No.19
Drugs & TargetsFree FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma May 08, 2020Vol.46 No.19
Drugs & TargetsFree Caris Life Sciences submits two PMA applications to FDA for whole exome and whole transcriptome sequencing May 08, 2020Vol.46 No.19
